Pablo Velazquez-Martin, MD
Kodiak Sciences Inc
10
0
3
N/A
0
6
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+1 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (10)
Research Network
Collaboration Network
Research Areas & Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Daniel Janer, MD
Kodiak Sciences Inc
Shared therapeutic areas:
Worked with same sponsors:
Hugo Quiroz-Mercado, MD
Asociación para Evitar la Ceguera en México
Shared therapeutic areas:
Oliver Findl, MD
Vienna Institute for Research in Ocular Surgery
Shared therapeutic areas:
Hamid Ahmadieh, MD
Ophthalmic Research Center of Shaheed Beheshti Medical University
Shared therapeutic areas:
Thomas A. Ciulla, MD
Midwest Eye Institute
Shared therapeutic areas:
Louis Glazer, MD
Vitreo-Retinal Associates
Shared therapeutic areas:
Robert S. Wirthlin, MD
Spokane Eye Clinic
Shared therapeutic areas:
Gerhard Garhöfer, MD
Department of Clinical Pharmacology, Medical University of Vienna
Shared therapeutic areas:
Chung-May Yang, MD
National Taiwan University Hospital
Shared therapeutic areas:
Brian B. Berger, MD
Retina Research Center
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (10)
Showing 10 of 10 trials
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO
All 10 trials loaded